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IVIanagement of Alcohol Withdrawal in the Critically 111 Patient: 
X Selected Review 
I Rebecca B. Kantz, RPh,* and H. Mathilda Horst, MD* 
Proper management of alcohol withdrawal represents a therapeutic challenge in the critically ill patient. The sever-
ity ofthe withdrawal syndrome varies with both the intensity and 
duration of the preceding alcohol exposure and may be compli-
cated by other diseases such as traumatic injury, alcoholic gas-
tritis, pancreatitis, liver failure, respiratory insufficiency, and/or 
malnutrition. These patients often cannot use the oral route for 
therapy, and demonstrate considerable variability in response to 
treatment modalities. 
Diagnosis 
Alcohol withdrawal may present a wide variety of clinical pat-
terns ranging from mild self-limiting hyperadrenergic state, 
tenned the common abstinence syndrome (CAS), to full-blown 
hallucinosis, grand mal seizures, and delirium tremens (DT's). 
CAS is characterized by tremor, anxiety, and diaphoresis and 
may occur as soon as six to eight hours after cessation of drink-
ing. Symptoms may occur alone or with auditory hallucinations 
and/or convulsions. Peak symptoms are seen within ten to 30 
hours and generally subside in 40 to 50 hours (1,2). Progression 
to DT's occurs in 1% to 10% of patients (1). Some authors feel 
that aggressive treatment of early symptoms will minimize pro-
gression to DT's; however, occasionally a patient will develop 
T's despite every preventive effort. 
DT's consist of profound disorientation associated with visual 
hallucinations and motor hyperactivity. The onset of DT's is 60 
to 80 hours after the last drink. The average duration of DT's is 
two and one-half days, but symptoms may persist for a week or 
more (1-3). 
Overlap in symptomatology may preclude a precise diagnosis 
in the critically ill patient (CAS versus DT's), although most au-
thors concur that symptoms are more easily controlled when 
agressively treated in the early stages (1). 
Tolerance 
Alcohol, unlike other central nervous system (CNS) depres-
santSj is metabolized primarily by the cytosolic liver enzyme 
alcohol dehydrogenase. Increased activity of this enzyme con-
tnbutes to the "tolerance" to alcohol displayed by heavy drink-
ers (2). In theory, tolerance and physical dependence on ethanol 
's a manifestation of compensatory neurophysiologic changes 
which offset the depressant effect of alcohol on neuronal excit-
ability, impulse conduction, and neurotransmitter release (4). 
Two methods have been suggested to aid the clinician in iden-
tifying the patient at risk of withdrawal (in addition to a positive 
history for withdrawal or DT's, which may not be elicited from 
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the critically ill patient) (1). Although withdrawal is thought to 
be a dose-dependent phenomenon, there is considerable indi-
vidual variation in the amount of alcohol consumption necessary 
to produce withdrawal. Furthermore, alcoholics are generally 
unreliable in reporting their tme alcohol intake. Blood alcohol 
concentrations may be used to detect tolerance; heavy imbibers 
may show no symptoms of intoxication with blood alcohol lev-
els which would render a nontolerant person intoxicated (100 to 
250 mg%) or unconscious (350 to 500 mg%). 
Since tolerance to other CNS depressant dmgs (barbiturates, 
benzodiazepines, and other sedatives) occurs concurrently with 
tolerance to alcohol (3), administration of a normally sedating 
dose of medication (50 mg secobarbital or chlordiazepoxide) to 
a tolerant individual may produce no sedation whatsoever This 
method may provide the clinician with another clue as to which 
patient is at risk for withdrawal. 
The theory behind pharmacologic treatment of alcohol with-
drawal syndrome is that of substituting a sedative agent which is 
cross-tolerant with alcohol, and then slowly weaning the patient 
from that agent to prevent precipitation of symptoms. Numerous 
pharmacologic agents have been used to treat alcohol with-
drawal syndrome, including phenothiazines, paraldehyde, ben-
zodiazepines, barbiturates, antihistamines, butyrophenones, 
beta-blockers, and ethanol (Table). Several studies have com-
pared the efficacy of the first four dmgs in this list (5-10). In 
combining the results of five of these studies, Thompson (3) 
found that patients treated with paraldehyde or benzodiaze-
pines had the lowest incidence of DT's and seizures, while the 
use of phenothiazines was associated with a greater incidence 
of seizures. (Often deaths reported in the entire study popu-
lation of 978 patients, nine patients had been treated with 
phenothiazines.) 
These studies were not controlled, and the dmg dosages em-
ployed varied widely. As there is no conclusive evidence as to 
which regimen is best, the choice of agent to control alcohol 
withdrawal syndrome must therefore be based on efficacy, avail-
ability, and lowest incidence of toxicity. Furthermore, the most 
appropriate regimen in the critically ill patient may be different 
from that used to treat a patient with uncomplicated withdrawal 
symptoms. 
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Table 
TVeatment of Alcohol Withdrawal in the Critically III 
Drug Route* 
Recommended 
Dose 
Dose 
Frequency 
Maximal 
Reported 
Dose Reference 
Chlordiazepoxide PO,lM,IVP 50 to 100 mg Every 6 hrs 1600 mg/day 1 
Diazapam PO,lM,lVP Sto 10 mg IV Every 5 min until 
calm then 
5 to 15 mg every 2 to 6 hrs l536 mg/48 hrs li 
Lorazepam PO,lM,lVP 2 to 8 mg Every 2 to 4 hrs Not available 
Haloperidol PO,lM,lVP 0.5 to 5 mg Every 2 to 6 hrs Not available 4,9,11,12 
Paraldehyde P0,1V, 10 to 170 mL Every 6 hrs 436 mU24 hrs 13 
rectal rectally 
Secobarbital IM 200 mg initially Every 6 hrs Not available 4,18,19 
then 100 to 200 mg 
Propranolol PO 40 mg Every 6 hrs Not available 16,17 
IV 0.5 mg Every 6 hrs 
•PO = orally, IM = intramuscular, IV = intravenous, and IVP = intravenous pu.sh. 
Phenothiazines are not widely recommended in the treatment 
of alcohol withdrawal syndrome since they have not been shown 
to be superior to other agents. In addition, phenothiazines lower 
seizure threshold, cause sedation, and may potentiate the hyper-
thermia seen in withdrawal (4,5,7-9). Antihistamines are con-
traindicated for this purpose and have anticholinergic effects 
that can cause tachycardia, somnolence, and hallucinations 
(4,9,11). 
Haloperidol, a butyrophenone and major tranquilizer, has 
been shown to be effective in controlling agitation, hallucina-
tions, and DT's with minimal side-effects (12). However, the 
ability ofthis dmg to lower seizure threshold is worrisome. For 
the treatment of withdrawal, haloperidol is recommended in in-
tramuscular (IM) doses of 0.5 to 2 mg every one to two hours 
until satisfactory response is achieved, then 2 to 5 mg IM every 
four to six hours (4,9,11,12). 
Paraldehyde is one of the classic dmgs used for alcohol with-
drawal. Paraldehyde is a short-acting sedative-hypnotic that has 
cross-tolerance with alcohol. It also has anticonvulsant activity 
which prevents progression to seizures or DT's when used early 
in withdrawal (3,5,8). Paraldehyde is not without its attendant 
problems, such as being erratically absorbed from the oral and 
rectal routes and causing sterile abscess formation with repeated 
IM injections. In a controlled comparison of rectally admin-
istered paraldehyde and intravenous diazepam to treat DT's, the 
diazepam-treated patients were calmed in one-half the time 
needed to calm the paraldehyde-treated patients. No adverse ef-
fects were noted with diazepam. One-half of the paraldehyde-
treated patients suffered adverse effects (13). Intravenous (IV) 
administration of paraldehyde has been associated with hy-
potension, pulmonary edema, metabolic acidosis, and liver 
toxicity (13-15). Paraldehyde is contraindicated in broncho-
pulmonary disease and hepatic insufficiency and would be of 
limited value in the critically i l l . 
Alcohol withdrawal is associated with an increase in urine and 
plasma catecholamines, and clinical features suggest a hyper-
adrenergic state. Beta-blockers such as propranolol have been 
effective in reducing tremor, blood pressure, heart rate, and cat-
echolamine levels in doses of 40 mg every six hours or 0.5 mg 
slow IV push (16,17). Propranolol is contraindicated in patients 
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with bronchospastic disease, heart failure, and insulin-depen-
dent diabetes. Efficacy studies of these agents in critically ill pa-
tients are lacking. 
Barbiturates are effective, inexpensive agents for alcohol 
withdrawal, provide sedation and anticonvulsant activity, and 
can be given intravenously (4,18,19). Pentobarbital and secobar-
bital have been used in doses of 200 mg IM initially, then 100 to 
200 mg IM every six hours. Despite favorable effects in control-
ling withdrawal, barbiturates have largely been replaced by 
newer agents. Phenobarbital (normal half-life two to five days) 
metabolism may be impaired in hepatic disease. Furthermore, 
combining phenobarbital with narcotic analgesics can poten-
tially cause oversedation in the critically ill patient (20,21). 
The administration of intravenous ethanol has been used as a 
5% solution in 5% dextrose at 150 mL/hr to prevent withdrawal 
symptoms (22). The drug has a narrow therapeutic index, a short 
half-life, and may perpetuate metabolic disturbances. Its use is 
not widely recommended (4). 
Many clinicians consider the benzodiazepines to be the 
agents of choice for the treatment of withdrawal due to their 
efficacy as well as their safety. These dmgs produce adequate 
sedation, anticonvulsant activity, and fewer side-effects than 
other agents. While control of withdrawal symptoms may be 
achieved with any benzodiazepine, only three agents are avail-
able in the parenteral form, lending themselves to treatment of 
the critically i l l patient; diazepam, chlordiazepoxide, and 
lorazepam. Rapid onset of action is achieved using the IV route, 
while IM injections may be absorbed erratically or incom-
pletely. Of these three agents, differences in pharmaco-
kinetic parameters may predispose one agent to be superior in 
treating alcohol withdrawal syndrome. 
Distribution 
The capacity of dmgs to cross the blood-brain barrier is deter-
mined in part by their inherent lipophilicity. While all ben-
zodiazepines are lipophilic, diazepam is more so than either 
chlordiazepoxide or lorazepam. Presumably owing to its 
lipophilic nature, diazepam also has a greater propensity fof 
peripheral distribution to nonblood compartments (adipose 
tissue). Following IV administration, diazepam has a rapid 
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onset of action, but CNS levels of the dmg fall rapidly, coincid-
ing with peripheral redistribution of the dmg. Lorazepam, how-
ever, is less lipophilic and has less propensity for peripheral 
redistribution. Thus, paradoxically, the "shorter acting" 
benzodiazepine (lorazepam T Vi = 10 hours) may have a longer 
acting clinical effect in the treatment of alcohol withdrawal than 
the "longer acting" diazepam (T Vi = 36 hours) and may re-
quire less frequent dosing (23-25). 
Metabolism 
Clinical side-effects of benzodiazepines (including respira-
tory depression) during chronic dosing may be the result of dmg 
accumulation. The longer the half-life of the dmg, the more ex-
tensive will be its accumulation. Lorazepam has the shortest 
half-life of the injectable benzodiazepines. This is due in part 
to diazepam and chlordiazepoxide being hepatically oxidized 
to active metabolites, whereas lorazepam forms an inactive 
glucuronide conjugate (23). 
Furthermore, these two metabolic pathways are differently 
influenced by factors altering the individual capacity for dmg 
biotransformation. Oxidation of diazepam and chlordiazepox-
ide may be impaired by liver disease (ie, cirrhosis), old age, or 
by coadministration of drugs (ie, cimetidine), further extending 
the half-life ofthese agents. Conjugation is not impaired by 
these same factors; thus inactivation of lorazepam is not influ-
enced by alcoholic cirrhosis (23,24). 
In dosing the benzodiazepines to treat alcohol withdrawal, 
several regimens have been reported to be successful. Chlor-
diazepoxide may be used in initial doses of 50 to 100 mg every 
six hours (IM or IV push). Doses of up to 1600 mg/day have been 
employed (1). 
Thompson et al (13) reported that patients with simple DT's 
required less than half the sedative dose required for calming 
than patients with associated pneumonia, hepatitis, or pan-
creatitis. Diazepam doses of 15 to 215 mg were required to ini-
tially calm patients, and total doses of 525 to 1355 mg were 
employed over six to 52 hours without excessive sedation (13). 
Thompson et al advocate initial treatment with 5 mg diazepam 
IV push every five minutes until the patient is calm but awake. 
(If agitation persi.sts after 30 minutes, the dosage can be dou-
bled.) Maintenance doses of 5 to 15 mg should be given every 
two to six hours until the patient has remained calm for 48 hours; 
then the doses can be tapered. 
Appropriate doses of lorazepam for alcohol withdrawal in the 
critically ill have not been identified. Conner et al (26) found that 
2 mg of lorazepam was as effective as 10 mg of diazepam in re-
lieving anxiety and providing preoperative sedation. 
Many therapeutic problems still exist in treating the critically 
'11 patient having alcohol withdrawal. Definitive means of pre-
tlicting progression to delirium tremens, as well as specific ways 
''f preventing this progression, are unavailable for this patient 
population. Studies comparing clinical efficacy of lorazepam, 
'Chlordiazepoxide, and diazepam in treating alcohol withdrawal 
"tthe critically til are lacking. No statistically significant dif-
ferences in efficacy among these agents have been demonstrated 
outpatients treated for alcohol withdrawal (27,28). Further tri-
als are needed in the critically ill to detect potential differences 
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in clinical efficacy among the benzodiazepines and to further de-
lineate optimal dosing regimens. 
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